Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab

BACKGROUND: Merkel cell carcinoma (MCC) is a rare and aggressive skin cancer, associated with a worse prognosis. The Immune Checkpoint Inhibitors (ICIs) avelumab and pembrolizumab have been recently approved as first-line treatment in metastatic MCC (mMCC). The clinical observation of improved outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Incorvaia, Lorena, Dimino, Alessandra, Algeri, Laura, Brando, Chiara, Magrin, Luigi, De Luca, Ida, Pedone, Erika, Perez, Alessandro, Sciacchitano, Roberta, Bonasera, Annalisa, Bazan Russo, Tancredi Didier, Li Pomi, Federica, Peri, Marta, Gristina, Valerio, Galvano, Antonio, Giuffrida, Dario, Fazio, Ivan, Toia, Francesca, Cordova, Adriana, Florena, Ada Maria, Giordano, Antonio, Bazan, Viviana, Russo, Antonio, Badalamenti, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149939/
https://www.ncbi.nlm.nih.gov/pubmed/37139149
http://dx.doi.org/10.3389/fonc.2023.1141500

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149939/
https://www.ncbi.nlm.nih.gov/pubmed/37139149
http://dx.doi.org/10.3389/fonc.2023.1141500

Ejemplares similares